GlassScriptPhysician profile
Laura M Taylor
NPI 1073827010
$27,153.35
in general payments reported to CMS, 2019-2025
29 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,207 · 2022: $2,836 · 2023: $3,215 · 2024: $3,631 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,075 · Travel and Lodging: $1,775 · Consulting Fee: $900 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,093.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,075.00 |
| Travel and Lodging | $1,774.66 |
| Consulting Fee | $900.00 |
| Education | $267.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,743.85 | 2021-2025 | |
| Janssen Biotech, INC. | $4,693.86 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $1,175.47 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,169.85 | 2021-2025 | |
| Ucb, INC. | $1,040.93 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $978.86 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $932.88 | 2021-2025 | Ilumya, Blu-U, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $644.31 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $592.31 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $591.71 | 2021-2025 | |
| Incyte Corporation | $480.05 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $473.46 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $427.86 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $315.68 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $310.44 | 2022-2025 | Nemluvio, Aklief |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $296.29 | 2021-2025 | |
| Almirall LLC | $204.92 | 2021-2025 | Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.17 | 2022-2025 | Spevigo |
| Epi Health, LLC | $179.74 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $175.24 | 2022-2025 | Siliq, Jublia, Cabtreo |
| Vyne Pharmaceuticals INC. | $134.86 | 2021 | |
| Verrica Pharmaceuticals INC. | $124.98 | 2025 | Ycanth |
| Dermavant Sciences, INC. | $100.26 | 2022-2024 | Vtama |
| Organon LLC | $44.07 | 2025 | Vtama |
| Mylan Institutional INC. | $36.90 | 2023 | Hulio |
| Strata Skin Sciences, INC. | $26.76 | 2025 | Xtrac |
| Merz North America, INC. | $23.28 | 2024 | |
| Emd Serono, INC. | $19.38 | 2021 | |
| Journey Medical Corporation | $12.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.